Matrixyl vs Retatrutide
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
MatrixylGLP-1 / Weight Loss Agonists
Retatrutide- Summary
- Matrixyl is the most widely used collagen-stimulating cosmetic peptide. As a matrikine — a fragment of type I procollagen — it signals skin cells to synthesize new collagen, elastin, and fibronectin, reducing wrinkle depth and improving skin firmness and elasticity.
- Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed an unprecedented average 24% body weight reduction at 48 weeks — exceeding any approved medication to date. It is in Phase 3 trials as of 2024.
- Half-Life
- N/A — topical; sustained signaling effects on fibroblasts persist beyond single application
- ~10–12 days
- Admin Route
- Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 3–8% concentration
- 0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
- Frequency
- Once or twice daily
- Once weekly
- Key Benefits
- Stimulates collagen I, III, and IV synthesis
- Increases fibronectin and glycosaminoglycan production
- Reduces wrinkle depth and length by 27–68% (studies)
- Improves skin firmness and elasticity
- Reduces dark circles and undereye bags
- Synergistic with retinol, vitamin C, and growth factors
- Suitable for all skin types including sensitive
- Well-studied with published clinical data
- ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
- Superior to both semaglutide and tirzepatide in early trial comparisons
- Triple receptor mechanism addresses multiple obesity pathways
- Significant reduction in liver fat (MASH/NAFLD indication being studied)
- Improved cardiovascular and metabolic markers
- Once-weekly dosing
- Potential for greatest weight loss of any currently investigated compound
- Side Effects
- Exceptional safety profile
- Non-irritating, suitable for sensitive skin
- No known adverse effects at cosmetic concentrations
- Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
- Diarrhea
- Constipation
- Heart rate increase (from glucagon receptor agonism)
- +2 more
- Stacks With
- —
- —